AU2012328679C1 - Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer - Google Patents

Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer Download PDF

Info

Publication number
AU2012328679C1
AU2012328679C1 AU2012328679A AU2012328679A AU2012328679C1 AU 2012328679 C1 AU2012328679 C1 AU 2012328679C1 AU 2012328679 A AU2012328679 A AU 2012328679A AU 2012328679 A AU2012328679 A AU 2012328679A AU 2012328679 C1 AU2012328679 C1 AU 2012328679C1
Authority
AU
Australia
Prior art keywords
fpsa
antibody
tumor
pct
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012328679A
Other languages
English (en)
Other versions
AU2012328679B2 (en
AU2012328679A1 (en
Inventor
Michael Evans
Jason Lewis
Hans LIJA
Charles Sawyers
David Ulmert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2012328679A1 publication Critical patent/AU2012328679A1/en
Publication of AU2012328679B2 publication Critical patent/AU2012328679B2/en
Application granted granted Critical
Publication of AU2012328679C1 publication Critical patent/AU2012328679C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
    • A61B5/4375—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the male reproductive system
    • A61B5/4381—Prostate evaluation or disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012328679A 2011-10-25 2012-10-25 Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer Active AU2012328679C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551195P 2011-10-25 2011-10-25
US61/551,195 2011-10-25
PCT/US2012/061982 WO2013063312A1 (en) 2011-10-25 2012-10-25 Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Publications (3)

Publication Number Publication Date
AU2012328679A1 AU2012328679A1 (en) 2014-06-12
AU2012328679B2 AU2012328679B2 (en) 2018-06-28
AU2012328679C1 true AU2012328679C1 (en) 2018-10-25

Family

ID=48168512

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012328679A Active AU2012328679C1 (en) 2011-10-25 2012-10-25 Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Country Status (7)

Country Link
US (3) US20140308204A1 (enExample)
EP (1) EP2771688B1 (enExample)
JP (2) JP6181059B2 (enExample)
CN (2) CN106872702A (enExample)
AU (1) AU2012328679C1 (enExample)
CA (1) CA2853705C (enExample)
WO (1) WO2013063312A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771688B1 (en) * 2011-10-25 2018-09-26 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
JP6493779B2 (ja) * 2014-09-19 2019-04-03 国立大学法人 岡山大学 ８９Ｚｒの標識方法
WO2017087826A1 (en) * 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
IL324632A (en) 2016-12-01 2026-01-01 Regeneron Pharma Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
WO2019133797A1 (en) * 2017-12-29 2019-07-04 Wu, Lester J. Benzenesulfonamide derivatives and method for modulating lipid raft
US20210196779A1 (en) * 2018-06-01 2021-07-01 Yale University Compositions and Methods for Treating Steroid Hormone-Related Diseases or Disorders
CN108802392A (zh) * 2018-08-29 2018-11-13 上海市东方医院 一种用于诊断前列腺癌的层析试纸条及其制备方法和应用
CN114324526B (zh) * 2021-12-27 2023-06-27 青岛农业大学 一种检测人血清中的前列腺特异性抗原的生物传感器及其制备方法和应用
WO2025208344A1 (zh) * 2024-04-02 2025-10-09 嘉兴允英医学检验有限公司 癌症风险等级预测模型生成和预测的方法和系统

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5308608A (en) 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5726304A (en) 1992-10-30 1998-03-10 The University Of British Columbia Porphocyanine and CNC-expanded porphyrins
US5405957A (en) 1992-10-30 1995-04-11 The University Of British Columbia Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6379669B1 (en) * 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
US5880145A (en) 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
NZ338031A (en) 1997-05-07 2001-04-27 Qlt Phototherapeutics Inc Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents and their use in conducting photodynamic diagnosis
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
US20060199230A1 (en) * 2005-03-03 2006-09-07 Hybritech Incorporated Use of prostate specific antigen to predict drug response
US20060211059A1 (en) 2005-03-18 2006-09-21 Taneja Samir S Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2771688B1 (en) 2011-10-25 2018-09-26 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
WO2017087826A1 (en) 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K PETTERSON ET AL. CLINICAL CHEMISTRY., AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, (199510), vol. 41, no. 10, ISSN 0009-9147, pages 1480 - 1488 *

Also Published As

Publication number Publication date
EP2771688A1 (en) 2014-09-03
US11446400B2 (en) 2022-09-20
CN104040341B (zh) 2016-12-28
US20230040245A1 (en) 2023-02-09
WO2013063312A1 (en) 2013-05-02
JP2017043634A (ja) 2017-03-02
AU2012328679B2 (en) 2018-06-28
US20190381200A1 (en) 2019-12-19
AU2012328679A1 (en) 2014-06-12
JP2015502339A (ja) 2015-01-22
EP2771688A4 (en) 2016-02-17
CA2853705C (en) 2021-10-12
EP2771688B1 (en) 2018-09-26
CN104040341A (zh) 2014-09-10
CN106872702A (zh) 2017-06-20
JP6181059B2 (ja) 2017-08-16
CA2853705A1 (en) 2013-05-02
US20140308204A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
US20230040245A1 (en) Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
US12383637B2 (en) Therapeutic agents and uses thereof
Zeglis et al. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels–Alder click chemistry
CN105085681B (zh) 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
Turker et al. An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis
WO2017087826A1 (en) Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
US20180243451A1 (en) Radiolabeled anti-glypican-3 immunoconjugates from immuno-pet imaging of hepatocellular carcinoma
Tu et al. Novel GRPR-targeting peptide for pancreatic cancer molecular imaging in orthotopic and liver metastasis mouse models
Wen et al. Synergism of 64Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect
Yang et al. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging
JP2008526979A (ja) 抗ｐｓｍａ抗体による併用癌治療法
US20160228589A1 (en) Methods and compositions for imaging disorders using polyspecific agents
Huynh et al. A comparison of 64Cu-labeled bi-terminally PEGylated A20FMDV2 peptides targeting integrin ανβ6
Khalid Chelation and Radiolabelling of Epithelial Cell Adhesion Molecule (EpCAM) and Transferrin Targeting Aptamers
Wyszatko CD133-Targeted Radionuclide Therapy and Molecular Imaging
Karkare Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUL 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 06 JUL 2018

FGA Letters patent sealed or granted (standard patent)